Role of positron emission tomography/computed tomography in bone malignancies

Radiologic Clinics of North America

Volumn 51, Issue 5, 2013, Pages 845-864

  Peller, Patrick J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bony metastasis; Fluorodeoxyglucose; Multiple myeloma; Osteosarcoma; PET CT; Positron emission tomography

Indexed keywords

BORTEZOMIB; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; THALIDOMIDE;

BONE CANCER; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHONDROSARCOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EWING SARCOMA; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOSARCOMA; PREVALENCE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME;

BONY METASTASIS; FLUORODEOXYGLUCOSE; MULTIPLE MYELOMA; OSTEOSARCOMA; PET/CT; POSITRON EMISSION TOMOGRAPHY;

BIOPSY; BONE NEOPLASMS; CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MULTIMODAL IMAGING; MULTIPLE MYELOMA; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84883447261     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2013.05.005     Document Type: Review

References (110)

1. Resnick D.L. Skeletal metastases. Diagnosis of bone and joint disorders 2002, 4274-4351. WB Saunders Co, Philadelphia. 4th edition. D.L. Resnick (Ed.).
2. Roodman G.D. Skeletal imaging and management of bone disease. Hematology Am Soc Hematol Educ Program 2008, 1:313.
3. Miller T.T. Bone tumors and tumorlike conditions: analysis with conventional radiography. Radiology 2008, 246:662-674.
4. Patel S.R., Zagars G.K., Pisters P.W. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003, 30(3):413-416.
5. Abdel-Dayem H.M. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl Med 1997, 27:355.
6. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002, 2:683.
7. Beyer T., Townsend D.W., Blodgett T.M. Dual-modality PET/CT tomography for clinical oncology. QJ Nucl Med 2002, 46:24.
8. Bruzzi J.F., Munden R.F., Truong M.T., et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics 2007, 27:1635-1652.
9. Truong M.T., Erasmus J.J., Macapinlac H.A., et al. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. JComput Assist Tomogr 2005, 29:205-209.
10. Gerth H.U., Juergens K.U., Dirksen U., et al. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. JNucl Med 2007, 48(12):1932-1939.
11. Kumar R., Chauhan A., Vellimana A.K., et al. Role of PET/PET-CT in the management of sarcomas. Expert Rev Anticancer Ther 2006, 6:1241.
12. Peterson J.J. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. Semin Musculoskelet Radiol 2007, 11:246-260.
13. Bastiannnet E., Groen H., Jager P.L., et al. The value of FDG-PET in the detection, grading, and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004, 30:83-101.
14. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10.
15. Smith M.A., Gurney J.G., Ries L.A. Cancer in adolescents 15 to 19 years old. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995 1999, SEER program, National Cancer Institute, Bethesda (MD), (Pub #99-4649). L.A. Ries, M.A. Smith, J.G. Gurney (Eds.).
16. Dorfman H.D., Czerniak B. Bone cancers. Cancer 1995, 75(Suppl 1):203-210.
17. Murphey M.D., Robbin M.R., Mcrae G.A., et al. The many faces of osteosarcoma. Radiographics 1997, 17(5):1205-1231.
18. McKenna R., Schwinn C., Soong K., et al. Sarcomas of the osteogenic series (osteosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases. JBone Joint Surg Am 1966, 48:1.
19. Heare T., Hensley M.A., Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr 2009, 21:365.
20. Bruland O.S., Høifødt H., Saeter G., et al. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005, 11:4666.
21. Federman N., Bernthal N., Eilber F.C., et al. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 2009, 10(1-2):82-93.
22. Burchill S.A. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. JClin Pathol 2003, 56(2):96-102.
23. Ludwig J.A. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008, 20(4):412-418.
24. Granowetter L., Womer R., Devidas M., et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. JClin Oncol 2009, 27:2536.
25. Gatta G., Capocaccia R., Stiller C., et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. JClin Oncol 2005, 23:3742.
26. Cotterill S.J., Ahrens S., Paulussen M., et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. JClin Oncol 2000, 18:3108.
27. Bertoni F., Bacchini P., Hogendoorn P.C.W. Chondrosarcoma. World Health Organization classification of tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 247-251. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
28. Murphey M.D., Walker E.A., Wilson A.J., et al. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics 2003, 23:1245.
29. Evans H.L., Ayala A.G., Romsdahl M.M. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977, 40:818.
30. Pring M.E., Weber K.L., Unni K.K., et al. Chondrosarcoma of the pelvis. A review of sixty-four cases. JBone Joint Surg Am 2001, 83-A:1630.
31. Fiorenza F., Abudu A., Grimer R.J., et al. Risk factors for survival and local control in chondrosarcoma of bone. JBone Joint Surg Br 2002, 84:93.
32. Giuffrida A.Y., Burgueno J.E., Koniaris L.G., et al. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. JBone Joint Surg Am 2009, 91(5):1063-1072.
33. Riedel R.F., Larrier N., Dodd L., et al. The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009, 10(1-2):94-106.
34. American Joint Committee on Cancer Staging manual 2010, 281. Spring, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
35. Wolf R.E., Enneking W.F. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am 1996, 27(3):473-481.
36. 18FDG-PET applications for cartilage neoplasms. Skeletal Radiol 2005, 34(7):367-374.
37. Franzius C., Bielack S., Flege S., et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. JNucl Med 2002, 43(8):1012-1017.
38. Franzius C., Sciuk J., Daldrup-Link H.E., et al. FDG PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000, 27(9):1305-1311.
39. Brenner W., Conrad E.U., Eary J.F. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004, 31(2):189-195.
40. Lee F.Y., Yu J., Chang S.S., et al. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. JBone Joint Surg Am 2004, 86(12):2677-2685.
41. Franzius C., Daldrup-Link H.E., Sciuk J., et al. FDG PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001, 12(4):479-486.
42. McCarville M.B., Christie R., Daw N.C., et al. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005, 184:1293.
43. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. JNucl Med 2003, 44(5):717-724.
44. Zwaga T., Bovée J.V., Kroon H.M. Osteosarcoma of the femur with skip, lymph node, and lung metastases. Radiographics 2008, 28(1):277-283.
45. 18F-FDG uptake as a predictor of patient outcome. JNucl Med 2008, 49(12):1973-1979.
46. O'Sullivan P.J., Rohren E.M., Madewell J.E. Positron emission tomography-CT imaging in guiding musculoskeletal biopsy. Radiol Clin North Am 2008, 46(3):475-486.
47. Bestic J.M., Peterson J.J., Bancroft L.W. Use of FDG PET in staging, restaging, and assessment of therapy response in Ewing sarcoma. Radiographics 2009, 29:1487-1501.
48. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 2006, 27(10):795-802.
49. Bredella M.A., Caputo G.R., Steinbach L.S. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002, 179(5):1145-1150.
50. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. JNucl Med 2009, 50(3):340-347.
51. Hamada K., Tomita Y., Inoue A., et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med 2009, 23(1):89-95.
52. Hawkins D.S., Rajendran J.G., Conrad U., et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002, 94:3277-3284.
53. Hawkins D.S., Schuetze S.M., Butrynski J.E., et al. [F-18]-fluorodeoxy-D-glucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. JClin Oncol 2005, 23:8828-8834.
54. Hawkins D.S., Conrad E.U., Butrynski J.E., et al. [F-18]-fluorodeoxy-D-glucose positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009, 115:3519-3525.
55. Schulte M., Brecht-Krauss D., Werner M., et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. JNucl Med 1999, 40:1637-1643.
56. 18F-FDG-PET. Ann Nucl Med 2008, 22:475-480.
57. 18F-FDG PET and MRI. JNucl Med 2009, 50(9):1435-1440.
58. Dimitrakopoulou-Strauss A., Strauss L.G., Heichel T., et al. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. JNucl Med 2002, 43(4):510-518.
59. Hamada K., Tomita Y., Konishi E., et al. FDG-PET evaluation of chondromyxoid fibroma of left ilium. Clin Nucl Med 2009, 34(1):15-17.
60. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584.
61. Yin J.J., Pollock C.B., Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005, 15:57.
62. Salmon J.M., Kilpatrick S.E. Pathology of skeletal metastases. Orthop Clin North Am 2000, 31:537-544.
63. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. JNucl Med 2005, 46(8):1356-1367.
64. Hamaoka T., Madewell J.E., Podoloff D.A., et al. Bone imaging in metastatic breast cancer. JClin Oncol 2004, 22(14):2942-2953.
65. Rybak L.D., Rosenthal D.I. Radiological imaging for the diagnosis of bone metastases. QJ Nucl Med 2001, 45(1):53-64.
66. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165.
67. Nielsen O.S., Munro A.J., Tannock I.F. Bone metastases: pathophysiology and management policy. JClin Oncol 1991, 9(3):509-524.
68. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987, 55:61.
69. Uematsu T., Yuen S., Yukisawa S., et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005, 184:1266-1273.
70. 18F-fluoride PET/CT. JNucl Med 2006, 47:287-297.
71. 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007, 72(Suppl 1):104-110.
72. Ng S.H., Chan S.C., Yen T.C., et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 2009, 36:12-22.
73. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. JClin Oncol 1998, 16:3375-3379.
74. Chang M.C., Chen J.H., Liang J.A., et al. Meta-analysis comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol 2012, 19(3):349-357.
75. Fogelman I., Cook G., Israel O., et al. Positron emission tomography and bone metastases. Semin Nucl Med 2005, 35:135-142.
76. Weber W.A. Assessing tumor response to therapy. JNucl Med 2009, 50(Suppl 1):1S-10S.
77. Tateishi U., Gamez C., Dawood S., et al. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008, 247:189-196.
78. 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007, 105:87-94.
79. 18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. JClin Oncol 2007, 25:3440-3447.
80. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer 2004, 101:2667.
81. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21.
82. Turesson I., Velez R., Kristinsson S.Y., et al. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010, 85:225.
83. Kumar S.K., Dingli D., Lacy M.Q., et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008, 83:614.
84. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. JClin Oncol 2006, 24:929.
85. Warsame R., Gertz M.A., Lacy M.Q., et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol 2012, 87(7):647-651.
86. Kyle R.A., Greipp P.R. Smoldering multiple myeloma. NEngl J Med 1980, 302:1347.
87. Kyle R.A., Remstein E.D., Therneau T.M., et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. NEngl J Med 2007, 356:2582.
88. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004, 79:859.
89. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Along-term study of prognosis in monoclonal gammopathy of undetermined significance. NEngl J Med 2002, 346:564.
90. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. JClin Oncol 2005, 23:3412.
91. Durie B.G., Salmon S.E. Aclinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842.
92. Dispenzieri A., Rajkumar S.V., Gertz M.A., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323.
93. Durie B.G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006, 42:1539-1543.
94. 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006, 33:525-531.
95. 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. JNucl Med 2008, 49:195-200.
96. 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007, 92:50-55.
97. Tan E., Weiss B.M., Mena E., et al. Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma 2011, 52(9):1630-1640.
98. Mulligan M.E., Badros A.Z. PET/CT and MR imaging in myeloma. Skeletal Radiol 2007, 36(1):5-16.
99. Mulligan M.E. Imaging techniques used in the diagnosis, staging, and follow-up of patients with myeloma. Acta Radiol 2005, 46(7):716-724.
100. Durie B.G., Waxman A.D., D'Agnolo A., et al. Whole-body (18)F-FDG PET identifies high-risk myeloma. JNucl Med 2002, 43(11):1457-1463.
101. 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys 2009, 74(3):740-746.
102. Schirrmeister H., Buck A.K., Bergmann L., et al. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003, 18(5):841-845.
103. Hur J., Yoon C.S., Ryu Y.H., et al. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. JComput Assist Tomogr 2007, 31:342-347.
104. Hall M.N., Jagannathan J.P., Ramaiya N.H., et al. Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. AJR Am J Roentgenol 2010, 195(5):1057-1065.
105. Varettoni M., Corso A., Pica G., et al. Incidence, presenting features and outcome of extraosseous disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010, 21:325-330.
106. 18F-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009, 114:2068-2076.
107. Dimitrakopoulou-Strauss A., Hoffmann M., Bergner R., et al. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med 2009, 34:576-584.
108. Zamagni F., Patriarca C., Nanni C., et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011, 118:5989-5995.
109. Zamagni E., Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012, 159(5):499-513. 10.1111/bjh.12007.
110. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer 2012, 118(8):1971-1981.